M. Sheets

发表

Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies,

Juswinder Singh, S. Ponader, M. Nacht, 2011 .

Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds*

Julie A. Wilkins, U. Warrior, Yung-wu Chen, 2001, The Journal of Biological Chemistry.

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Xiaoping Zhou, U. Warrior, C. Wegner, 2000, Journal of medicinal chemistry.

Inhibition of p56lckTyrosine Kinase by Isothiazolones

U. Warrior, Yung-wu Chen, P. Wiedeman, 1999 .

A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.

J. Trevillyan, G. Carter, K. Marsh, 1999, The Journal of investigative dermatology.

TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators.

Julie A. Wilkins, U. Warrior, M. Nakane, 2002, Cellular immunology.

A High-Capacity Scintillation Proximity Assay for the Discovery and Evaluation of ZAP-70 Tandem SH2 Domain Antagonists

U. Warrior, H. Yoon, J. Trevillyan, 1998 .

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Juswinder Singh, M. Nacht, R. Petter, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

P. Wiedeman, J. Trevillyan, K. Marsh, 1998, Current pharmaceutical design.

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Juswinder Singh, R. T. Sjin, M. Nacht, 2012 .

Development of a p38 Kinase Binding Assay for High Throughput Screening

R. Simmer, U. Warrior, D. Burns, 1999, Journal of biomolecular screening.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Juswinder Singh, W. Pao, T. van Dyke, 2013, Cancer discovery.

Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

Juswinder Singh, M. Nacht, L. Qiao, 2013, Journal of medicinal chemistry.

In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Juswinder Singh, M. Nacht, M. Raponi, 2014, Molecular Cancer Therapeutics.

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

Nicolas Stransky, C. Lengauer, C. Winter, 2015, Cancer discovery.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Yoon-Koo Kang, K. Hoeflich, C. Lengauer, 2019, Cancer discovery.

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung-wu Chen, J. Trevillyan, G. Carter, 2007, Journal of cardiovascular pharmacology.

Inhibition of p56(lck) tyrosine kinase by isothiazolones.

U. Warrior, P. Wiedeman, J. Trevillyan, 1999, Archives of biochemistry and biophysics.

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Juswinder Singh, Juswinder Singh, Hugues Bernard, 2011, Nature chemical biology.

Prolonged Inhibition of BCR Signaling and Suppression of B Cell Lymphoma through Irreversible Inhibition of Bruton’s Tyrosine Kinase

Juswinder Singh, Hugues Bernard, M. Nacht, 2008 .

Small Molecule Therapeutics In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Juswinder Singh, M. Nacht, M. Raponi, 2014 .

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Juswinder Singh, Hugues Bernard, M. Nacht, 2011, Nature chemical biology.